Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07300943 · ClinicalTrials.gov registry record · Phase 1

Study in Advanced Solid Tumor Patients

A Phase 1 study of Advanced Solid Tumor, sponsored by Callio Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
306
Enrollment target
11
Study locations

NCT07300943: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Callio Therapeutics.

NCT07300943 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Callio Therapeutics. The registered enrollment target is 306 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (60% higher). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07300943, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Callio Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
306 participants
Enrollment target
11
Study locations

Study Summary

The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2: Tumor-Specific Expansions with Dose Optimization, Phase 2 will further evaluate CLIO-8221 in tumor-specific expansion cohorts to optimize dosing and assess preliminary efficacy.

Primary Outcome

Type, incidence, severity, and seriousness of AEs occurred

Conditions Studied

Interventions

  • DRUG CLIO-8221

Study Locations (11)

Victoria

  • Peter Maccallum Cancer Centre - Box Hill
  • AlfredHealth - Heidelberg
  • Royal Melbourne Hospital - Melbourne

Texas

  • MD Anderson Cancer Center - Houston
  • START San Antonio - San Antonio

Massachusetts

  • DFCI - Boston

Tennessee

  • Sarah Cannon Research Institute 335 24th Avenue North, Suite 400 - Nashville

Utah

  • START Mountain - West Valley City

New South Wales

  • Scientia Clinical Research - Randwick

Queensland

  • Integrated Clinical Oncology Network Pty Ltd - South Brisbane

Western Australia

  • Linear Clinical Research Ltd - Nedlands

Trial Details

FieldValue
Enrollment Target 306 participants
Start Date 2026-02-28
Est. Completion 2028-07-17
Phase Phase 1
Callio Therapeutics

1 total trials

What NCT07300943 shows while recruiting

NCT07300943 is an interventional study that assigns participants to a tested intervention. The registered 306 participants enrollment target is mid-sized for trials with a published cap, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (60% higher).

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which CLIO-8221 is the first listed.

NCT07300943 lists 11 locations in 8 states (Victoria, Texas, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT07300943 about?

NCT07300943 is a clinical study titled "Study in Advanced Solid Tumor Patients". The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2: Tumor-Specific Expansions with Dose Optimization, Phase 2 will further evaluate CLIO-8221 in tumor...

What is the current status of trial NCT07300943?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 306 participants. The study started on 2026-02-28. Estimated completion is 2028-07-17.

What conditions does trial NCT07300943 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT07300943?

The interventions under investigation include: CLIO-8221 (DRUG).

Who is sponsoring clinical trial NCT07300943?

This trial is sponsored by Callio Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07300943 being conducted?

This trial has 11 study locations across Massachusetts, Tennessee, Texas, Utah, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07300943's enrollment target sits among peer trials

306 37th of 189 higher than 153 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05078970 · 306 participants · NA

    Advancing Suicide Intervention Strategies for Teens During High Risk Periods

  • NCT05843695 · 306 participants · NA

    Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety

  • NCT06057337 · 306 participants · NA

    Families With Pride ("Familias Con Orgullo").

  • NCT06498635 · 306 participants · Phase 3

    Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07300943, the US trial registry maintained by the National Library of Medicine. NCT07300943 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.